The Immune System in End Stage CKD Patients - Comparison Among Different Modalities of RRT

Overview

The evaluation and assessment of the influence of the different modalities of renal replacement therapy (RRT), including peritoneal dialysis (PD), conventional hemodialysis with high flux dialyzers, hemodiafiltration (HDF) and expanded hemodialysis (HDx) with Medium Cut Off (MCO) dialyzers on the levels of the cell subsets of the innate and acquired immune system as well as the investigation of the possible role of these cells as prognostic indices of morbidity and mortality in patients with end-stage Chronic Kidney Disease (CKD) undergoing different modalities of RRT.

The sustained inflammatory state in CKD is of complex pathogenesis and is believed to be in part attributable to the augmented activation of innate immune system cell subsets. The activation of the innate immune system plays an essential role within all the spectrum of cardiovascular disease in CKD, including accelerated atherosclerosis, left ventricular hypertrophy and heart failure. However, the intricate immunological mechanisms involved in the pathogenesis of CKD-associated cardiovascular disease remain to be clarified.The hemodialysis procedure itself is associated with an increased inflammatory burden. Considering the fact that middle molecules lie at the crossroads of chronic inflammation and immune dysregulation, oxidative stress as well as cardiovascular morbidity of CKD, efforts have focused on improving the clearance of larger middle molecules in dialysis. Hemodiafiltration is considered to further improve the clearance of larger toxins by utilizing large-volume ultrafiltration, also known as convection. HDF compared with standard hemodialysis, may have beneficial effects with regard to micro-inflammation, as indicated by lower levels of inflammatory markers, C-reactive protein (CRP), and Interleukin 6 (IL-6). However, evidence from large outcome trials comparing HDF to hemodialysis is controversial The introduction of the newest generation of highly selective and permeable MCO, which have an increasingly porous membrane but with tightened distribution of pore sizes, is associated with increased removal of large middle-molecules up to a molecular weight of 45,000 Dalton (Da). On the other hand safety concerns regarding MCO membranes such as albumin loss and back filtration of endotoxins have proven to be inconsistent by clinical studies run so far. Accordingly the clinical benefits of MCO membranes with regard to patient outcomes,chronic inflammation, immune dysregulation, atherosclerosis or structural heart disease, remains to be evaluated by future clinical studies. Until now there are no data regarding the effects of expanded hemodialysis on immune cell subsets or comparative studies regarding the influence of the currently available methods of RRT on immune cell subsets with expanded hemodialysis. Whether expanded hemodialysis with MCO membranes is associated with "improved" patterns of immune cell subsets with regard to chronic micro-inflammation as compared to the currently available methods, including HDF, and whether this translates into improved clinical outcomes remains to be elucidated, this being the aim of our study. 30 patients undergoing conventional hemodialysis and 15 patients undergoing PD will be enrolled in the study. The study will be designed in two arms - the cross-sectional arm and the prospective arm during which patients will be under follow-up for 12 months. The cross-sectional study: Immune cell subtypes will be measured at baseline in all patients. In patients undergoing hemodialysis, measurements will be performed in the midweek dialysis session and for PD patients during a programmed visit at the PD unit. Regarding patients undergoing conventional hemodialysis: * 15 of those undergoing conventional hemodialysis with high-flux dialyzers will be allocated to online-HDF with the same dialyzer and 15 hemodialysis patients undergoing hemodialysis with a high-flux dialyzer will be allocated to HDx with MCO dialyzers (THERANOVA dialyzer, Baxter International Inc. (NYSE: BAX)), for 12 consecutive weeks. Immune cell subtypes will be measured in the midweek dialysis session of the 12th week. * subsequently both groups will be allocated to conventional hemodialysis with the same dialyzer as baseline for another 4 weeks as a wash-out phase and thereafter they will be crossed over to online-HDF and HDx with the THERANOVA dialyzer for another 12 week period. Immune cell subtypes will be measured in the midweek dialysis session of the 28th week. Thereafter, patients will proceed with the hemodialysis modality, which they were allocated to during the last 12 weeks of the study and immune cell subtypes will be measured 20 weeks later. The overall duration of the study will be 48 weeks. Immune cell subtypes will be measured in the midweek dialysis session of the 48th week. Regarding peritoneal dialysis, immune cell subtypes will be measured at baseline and at 48 weeks. The evaluation of the immune cells subtypes will be done by flow-cytometry of peripheral blood. The following cell types will be measured: 1. CD14++C16-, CD14+CD16+, CD 14+CD16++ subpopulations of monocytes 2. Natural Killers (NK cells 3. CD4+ lymphocytes and CD8+ lymphocytes 4. CD 4+CD25+ Τ regulatory lymphocytes (Tregs) (CD = Cluster of Differentiation) Demographic data and anthropometric data, major cardiovascular risk factors, the cause of end-stage CKD, co-morbidities and medical treatment shall be recorded for all patients at baseline. A cardiovascular workout will take place. All hemodialysis patients will undergo at baseline, week 12 and week 28: * echocardiographic evaluation with estimation of classical and novel echocardiographic parameters of systolic and diastolic left ventricular function, * ABP (Ambulatory Blood Pressure) monitoring * Carotid Doppler for the estimation of intima-media thickness (IMT) * Lung ultrasound for the assessment of lung comets PD patients shall undergo the same diagnostic procedures as hemodialysis patients at baseline and at week 48. Additional routine blood test examinations shall be performed monthly, including complete blood count and biochemical blood tests including glucose, blood urea nitrogen (BUN), creatinine, potassium, sodium, calcium, phosphate, serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), creatine kinase (CPK), gamma-glutamyltransferase (γGT), alkaline phosphatase (ALP), proteins and albumin, immunoglobulins, lipid panel - total cholesterol, triglycerides, low-density lipoproteins (LDL), high-density lipoproteins (HDL) - uric acid, iron, total iron binding capacity (TIBC), ferritin, parathyroid hormone (PTH), vitamin D, CRP, erythrocyte sedimentation rate (ESR), fibrinogen. Dialysis adequacy (monthly KT/V, urea reduction rate (URR) in hemodialysis patients and quarterly KT/V, residual renal function as well as peritoneal function testing in PD patients shall be regularly monitored according to international guidelines. Nutritional parameters and hydration status shall be evaluated at baseline, at week 12 and at week 28 in hemodialysis patients and quarterly in PD patients. During the prospective arm of the study (12 months) data regarding technique failure, infections, hospitalizations for any cause and major cardiovascular events (acute coronary syndrome, cerebrovascular accident, heart failure, peripheral vascular disease, sudden cardiac death) and death from any cause will be recorded.

Conditions

Eligibility

Locations (1)

Outcomes

Central Contacts